KEYNOTE-240 : A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Liver<br/>CancersCancer LocationLiver
Cancers

Systemic therapy | Stomach and upper gastrointestinal tractLiver

Trial Overview Read MoreRead more

This phase III trial is evaluating pembrolizumab in patients who have previously received systemic treatment for advanced hepatocellular (liver) cancer.
 

This trial is treating patients with Hepatocellular (Liver) Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma

Commercial Sponsor

Merck

Summary

This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC).The primary objectives of this study are to determine 1) Progression-Free Survival (PFS) and 2) Overall Survival (OS) of pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC. The primary hypotheses of this study are: 1) pembrolizumab plus BSC prolongs PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, assessed by a blinded central imaging vendor compared to placebo plus BSC, and 2) pembrolizumab plus BSC improves OS compared with placebo plus BSC.

Recruiting Hospitals Read MoreRead more

Monash Health Liver Unit
Clayton
Mr Paul O'Neill

03 9594 3089

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next